No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women

Bone

Volumn 40, Issue 1, 2007, Pages 175-181

  Ueland, T ^a,b   Bollerslev, J ^a,c   Wilson, S G ^c,d   Dick, I M ^c,d   Islam, F M A ^c,d   Mullin, B H ^c,d   Devine, A ^c,d   Prince, R L ^c,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Osteoporosis; Osteoprotegerin; Postmenopausal; Single nucleotide polymorphisms

Indexed keywords

OSTEOPROTEGERIN;

AGED; ARTICLE; BONE DENSITOMETRY; BONE MASS; ETHNIC GROUP; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HIP; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; SERUM; SINGLE NUCLEOTIDE POLYMORPHISM; ULTRASOUND;

AGED; AGED, 80 AND OVER; AUSTRALIA; BONE AND BONES; BONE DENSITY; COHORT STUDIES; DENSITOMETRY, X-RAY; FEMALE; FRACTURES, SPONTANEOUS; GENE FREQUENCY; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; OSTEOPOROSIS; OSTEOPROTEGERIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33751536723     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.06.022     Document Type: Article

References (38)

1. Pocock N.A., Eisman J.A., Hopper J.L., Yeates M.G., Sambrook P.N., and Eberl S. Genetic determinants of bone mass in adults. A twin study. J. Clin. Invest. 80 (1987) 706-710
2. Melton III L.J., Atkinson E.J., O'Fallon W.M., Wahner H.W., and Riggs B.L. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J. Bone Miner. Res. 8 (1993) 1227-1233
3. Hofbauer L.C., and Schoppet M. Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. J. Clin. Endocrinol. Metab. 87 (2002) 4078-4079
4. Hofbauer L.C., and Heufelder A.E. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J. Mol. Med. 79 (2001) 243-253
5. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
6. Takahashi N., Udagawa N., and Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256 (1999) 449-455
7. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 3597-3602
8. Shevde N.K., Bendixen A.C., Dienger K.M., and Pike J.W. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7829-7834
9. Srivastava S., Toraldo G., Weitzmann M.N., Cenci S., Ross F.P., and Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276 (2001) 8836-8840
10. Morinaga T., Nakagawa N., Yasuda H., Tsuda E., and Higashio K. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. Eur. J. Biochem. 254 (1998) 685-691
11. Arko B., Prezelj J., Komel R., Kocijancic A., Hudler P., and Marc J. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 87 (2002) 4080-4084
12. Jorgensen H.L., Kusk P., Madsen B., Fenger M., and Lauritzen J.B. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J. Bone Miner. Metab. 22 (2004) 132-138
13. Langdahl B.L., Carstens M., Stenkjaer L., and Eriksen E.F. Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures. J. Bone Miner. Res. 17 (2002) 1245-1255
14. Yamada Y., Ando F., Niino N., and Shimokata H. Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. Mol. Genet. Metab. 80 (2003) 344-349
15. Bollerslev J., Wilson S.G., Dick I.M., Devine A., Dhaliwal S.S., and Prince R.L. Calcium-sensing receptor gene polymorphism A986S does not predict serum calcium level, bone mineral density, calcaneal ultrasound indices, or fracture rate in a large cohort of elderly women. Calcif. Tissue Int. 74 (2004) 12-17
16. Dick I.M., Devine A., Marangou A., Dhaliwal S.S., Laws S., Martins R.N., et al. Apolipoprotein E4 is associated with reduced calcaneal quantitative ultrasound measurements and bone mineral density in elderly women. Bone 31 (2002) 497-502
17. Ireland P., Jolley D., Giles G., O'Dea K., Powles J.R.I., Wahlqvist M.L., et al. Development of the Melbourne FFQ: a food frequency questionnaire for use in an Australian prospective study involving an ethnically diverse cohort. Asia Pac. J. Clin. Nutr. 1 (1994) 19-31
18. Ueland T., Bollerslev J., Godang K., Muller F., Froland S.S., and Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-Possible role in bone homeostasis. Eur. J. Endocrinol. 145 (2001) 685-690
19. Price P.A., and Nishimoto S.K. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 2234-2238
20. Randall A.G., Kent G.N., Garcia-Webb P., Bhagat C.I., Pearce D.J., Gutteridge D.H., et al. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. J. Bone Miner. Res. 11 (1996) 1176-1184
21. McCloskey E.V., Spector T.D., Eyres K.S., Fern E.D., O'Rourke N., Vasikaran S., et al. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos. Int. 3 (1993) 138-147
22. Wise C.A., Paris M., Morar B., Wang W., Kalaydjieva L., and Bittles A.H. A standard protocol for single nucleotide primer extension in the human genome using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 17 (2003) 1195-1202
23. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 25 (2003) 115-121
24. K.W. Carter, P.A. McCaskie, L.J. Palmer, JLIN: a Java based Linkage Disequilibrium plotter. [online] http://www.genepi.org.au/projects/jlin_2004.
25. Yano K., Tsuda E., Washida N., Kobayashi F., Goto M., Harada A., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res. 14 (1999) 518-527
26. Ueland T., Brixen K., Mosekilde L., Mosekilde L., Flyvbjerg A., and Bollerslev J. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. J. Clin. Endocrinol. Metab. 88 (2003) 1014-1018
27. Browner W.S., Lui L.Y., and Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 86 (2001) 631-637
28. Kannus P., Parkkari J., Sievanen H., Heinonen A., Vuori I., and Jarvinen M. Epidemiology of hip fractures. Bone 18 (1996) 57S-63S
29. Brandstrom H., Stiger F., Lind L., Kahan T., Melhus H., and Kindmark A. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem. Biophys. Res. Commun. 293 (2002) 13-17
30. Soufi M., Schoppet M., Sattler A.M., Herzum M., Maisch B., Hofbauer L.C., et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J. Clin. Endocrinol. Metab. 89 (2004) 3764-3768
31. Wynne F., Drummond F., O'Sullivan K., Daly M., Shanahan F., Molloy M.G., et al. Investigation of the genetic influence of the OPG, VDR (Fok1), and COLIA1 Sp1 polymorphisms on BMD in the Irish population. Calcif. Tissue Int. 71 (2002) 26-35
32. Ohmori H., Makita Y., Funamizu M., Hirooka K., Hosoi T., Orimo H., et al. Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis. J. Hum. Genet. 47 (2002) 400-406
33. Brandstrom H., Gerdhem P., Stiger F., Obrant K.J., Melhus H., Ljunggren O., et al. Single nucleotide polymorphisms in the human gene for osteoprotegerin are not related to bone mineral density or fracture in elderly women. Calcif. Tissue Int. 74 (2004) 18-24
34. Attia J., Thakkinstian A., and D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J. Clin. Epidemiol. 56 (2003) 297-303
35. Browner W.S., Lui L.Y., and Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 86 (2001) 631-637
36. Abrahamsen B., Hjelmborg J.V., Kostenuik P., Stilgren L.S., Kyvik K., Adamu S., et al. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone 36 (2005) 727-735
37. Rogers A., Saleh G., Hannon R.A., Greenfield D., and Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J. Clin. Endocrinol. Metab. 87 (2002) 4470-4475
38. Mezquita-Raya P., de la H.M., Garcia D.F., Alonso G., Ruiz-Requena M.E., and de Dios L.J. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos. Int. 38 (2005) 1368-1374